How Amphista Therapeutics is positioning non-cereblon degraders for next-generation oncology pipelines
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Vyome’s VT-1953 Phase 2 data signals breakthrough in malignant fungating wound care
Vyome’s VT-1953 shows strong Phase 2 results in cancer wound care. Find out how this breakthrough could reshape supportive oncology treatment today.
Can Annamycin bridge cytotoxic therapy and immunotherapy in pancreatic cancer?
Find out how Annamycin could bridge chemotherapy and immunotherapy in pancreatic cancer and what AACR 2026 data signals for future trials.
STK-012 shows promise in resistant lung cancer biology, but can Synthekine deliver in Phase 2?
Synthekine’s STK-012 showed encouraging AACR 2026 data in resistant NSCLC. Read what the results could mean for frontline lung cancer treatment.
Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.
Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
Takara Bio USA says Trekker FX outperformed conventional spatial methods in a cancer benchmark study. Read what this could mean for oncology research.
Palleon Pharmaceuticals tests B7-H3-targeted sialidase in ovarian cancer, what changes now?
Palleon Pharmaceuticals has moved E-688/HLX316 into human testing. Read why this B7-H3 sialidase could reshape immuno-oncology.
Can Debiopharm turn a Fast Track win into a real ovarian cancer breakthrough?
Debiopharm’s ovarian cancer combo won FDA Fast Track after AACR 2026 data. Read what it means for DDR therapy, biomarkers, and clinical risk.
Can Whitehawk Therapeutics turn preclinical ADC depth into a real oncology pipeline advantage?
Whitehawk Therapeutics unveiled AACR 2026 data for three ADCs. Read what it means for pipeline differentiation, risk, and investor sentiment.
Why CStone Pharmaceuticals’ CS5007 may be the most important asset in its AACR 2026 antibody-drug conjugate update
CStone Pharmaceuticals unveiled three ADC programs at AACR 2026. Read what CS5007, CS5006, and CS5008 could mean for oncology development.